MyHand-SCI: an Active Hand Orthosis for Spinal Cord Injury
Launched by COLUMBIA UNIVERSITY · Sep 21, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The MyHand-SCI clinical trial is focused on developing and testing a special device designed to help people with spinal cord injuries (specifically those with injuries at the C6-C7 level) improve their hand function. The device, called an active hand orthosis, aims to assist individuals who have difficulty using their hands and fingers due to reduced strength and control caused by their injury. This study is currently recruiting participants aged 65 to 74 who have been living with their injury for at least six months and are able to give their consent to participate.
To be considered for this trial, potential participants should have a C6-C7 spinal cord injury and experience challenges with moving their hands and fingers. However, individuals with certain conditions, such as severe muscle stiffness, fixed arm positions that limit hand use, or active wounds on their arms, will not be eligible. Participants in the trial can expect to work with researchers to test how well this new device can help them regain some hand function, potentially improving their day-to-day activities. This is an exciting opportunity for those looking to enhance their quality of life after a spinal cord injury.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Individuals with C6-C7 spinal cord injury, at least 6-months post-injury with impaired upper limb function
- • Substantially reduced motor control and strength below the level of their SCI with regard to hand and finger function
- • Able to provide informed consent
- Exclusion Criteria:
- • Fixed upper limb contractures that limit functional use of the hand and arm or ability to use the device
- • Severe spasticity (modified Ashworth \>2) at elbow, wrist, or fingers
- • Any open wounds or unusual skin fragility
- • Persistent severe pain in their upper limb
About Columbia University
Columbia University, a prestigious Ivy League institution located in New York City, is a leading sponsor of clinical trials dedicated to advancing medical research and improving patient care. With a robust network of research facilities and a commitment to innovation, Columbia University collaborates with a diverse range of healthcare professionals and researchers to explore groundbreaking therapies and treatment methodologies. The university's clinical trials encompass various fields, including oncology, neurology, and public health, aiming to translate scientific discoveries into effective clinical applications. Columbia University is dedicated to maintaining the highest ethical standards and regulatory compliance, ensuring the safety and well-being of trial participants while contributing to the global body of medical knowledge.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
New York, New York, United States
Patients applied
Trial Officials
Joel Stein, MD
Principal Investigator
Columbia University
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials